Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

To: MFG ENG who wrote (49645)	1/23/2019 5:36:07 AM
From: ghettogoulash	11 Recommendations Read Replies (1) of 63283

I'm not sure why you are still talking about the 483 when Morgan Stanley just said, even as they simultaneously downgraded us a notch: "Mgt. indicated these issues are NOT related to the prior issues raised in the FDA 483 letter from the summer." Nevertheless, your informative and acutely specialized analyses do unveil the rigorous, almost mind-blowing specifications involved in getting this drug to the market. according to trusted sources

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next